UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 149

Sortiert nach

Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies

British journal of cancer, 2023-10, Vol.129 (9), p.1389-1396

2023

Volltextzugriff (PDF)

Reactive astrocytic S1P3 signaling modulates the blood-tumor barrier in brain metastases

Nature communications, 2018-07, Vol.9 (1), p.2705-18, Article 2705

2018

Volltextzugriff (PDF)

Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors

Molecular cancer therapeutics, 2018-08, Vol.17 (8), p.1694-1704

2018

Volltextzugriff (PDF)

Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma

Molecular cancer therapeutics, 2020-11, Vol.19 (11), p.2308-2318

2020

Volltextzugriff (PDF)

Metastasis-Specific Gene Expression in Autochthonous and Allograft Mouse Mammary Tumor Models: Stratification and Identification of Targetable Signatures

Molecular cancer research, 2020-09, Vol.18 (9), p.1278-1289

2020

Volltextzugriff (PDF)

Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment

Translational oncology, 2022-07, Vol.21, p.101440-101440, Article 101440

2022

Volltextzugriff (PDF)

Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers

Frontiers in oncology, 2024, Vol.14, p.1386190-1386190

2024

Volltextzugriff (PDF)

Dual mTORC1/2 inhibition compromises cell defenses against exogenous stress potentiating Obatoclax-induced cytotoxicity in atypical teratoid/rhabdoid tumors

Cell death & disease, 2022-04, Vol.13 (4), p.410-14, Article 410

2022

Volltextzugriff (PDF)

Diabetic cardiomyopathy-associated dysfunction in spatially distinct mitochondrial subpopulations

American journal of physiology. Heart and circulatory physiology, 2009-02, Vol.296 (2), p.H359-H369

2009

Volltextzugriff (PDF)

Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells

Clinical cancer research, 2016-03, Vol.22 (5), p.1197-1210

2016

Volltextzugriff (PDF)

Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma

Pigment cell and melanoma research, 2016-11, Vol.29 (6), p.643-655

2016

Volltextzugriff (PDF)

Defective Cytochrome P450-Catalysed Drug Metabolism in Niemann-Pick Type C Disease

PloS one, 2016-03, Vol.11 (3), p.e0152007-e0152007

2016

Volltextzugriff (PDF)

Pharmacokinetics and tolerability of the dual TORC1/2 inhibitor sapanisertib in combination with the MEK inhibitor trametinib in dogs

Frontiers in veterinary science, 2022-12, Vol.9, p.1056408-1056408

2022

Volltextzugriff (PDF)

Pulmonary tumor thrombotic microangiopathy and pulmonary veno-occlusive disease in a woman with cervical cancer treated with cediranib and durvalumab

BMC pulmonary medicine, 2018-07, Vol.18 (1), p.112-112, Article 112

2018

Volltextzugriff (PDF)

Systemic immune changes accompany combination treatment with immunotoxin LMB‐100 and nab‐paclitaxel

Cancer medicine (Malden, MA), 2023-02, Vol.12 (4), p.4236-4249

2023

Volltextzugriff (PDF)

A Quantitative Pharmacology Model of Exosome-Mediated Drug Efflux and Perturbation-Induced Synergy

Pharmaceutics, 2021-06, Vol.13 (7), p.997

2021

Volltextzugriff (PDF)

Development and utilization of a combined LC–UV and LC–MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2012-06, Vol.898, p.32-37

2012

Volltextzugriff (PDF)

PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics

Seminars in oncology, 2024-02, Vol.51 (1-2), p.19-24

2024

Volltextzugriff (PDF)

First‐in‐Human Phase I Study of Envafolimab, a Novel Subcutaneous Single‐Domain Anti‐PD‐L1 Antibody, in Patients with Advanced Solid Tumors

The oncologist (Dayton, Ohio), 2021-09, Vol.26 (9), p.e1514-e1525

2021

Volltextzugriff (PDF)

Ibrutinib's off-target mechanism: cause for dose optimization

Cancer biology & therapy, 2021-12, Vol.22 (10-12), p.529-531

2021

Volltextzugriff (PDF)

Dose Optimization of Pembrolizumab: Less May Be More

Clinical pharmacology and therapeutics, 2022-05, Vol.111 (5), p.993-993

2022

Volltextzugriff (PDF)

IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion

Clinical cancer research, 2019-08, Vol.25 (16), p.4945-4954

2019

Volltextzugriff (PDF)

1 – 25 von 149

Suche als RSS-Feed

Aktive Filter

KollektionIngenta.com

ThemaMale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(143)
Mit Volltextzugriff
(139)

Publikationsform

Sprache

Englisch
(149)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies

Reactive astrocytic S1P3 signaling modulates the blood-tumor barrier in brain metastases

Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors

Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma

Metastasis-Specific Gene Expression in Autochthonous and Allograft Mouse Mammary Tumor Models: Stratification and Identification of Targetable Signatures

Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment

Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers

Dual mTORC1/2 inhibition compromises cell defenses against exogenous stress potentiating Obatoclax-induced cytotoxicity in atypical teratoid/rhabdoid tumors

Diabetic cardiomyopathy-associated dysfunction in spatially distinct mitochondrial subpopulations

Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells

Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma

Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma

Defective Cytochrome P450-Catalysed Drug Metabolism in Niemann-Pick Type C Disease

Pharmacokinetics and tolerability of the dual TORC1/2 inhibitor sapanisertib in combination with the MEK inhibitor trametinib in dogs

Pulmonary tumor thrombotic microangiopathy and pulmonary veno-occlusive disease in a woman with cervical cancer treated with cediranib and durvalumab

Systemic immune changes accompany combination treatment with immunotoxin LMB‐100 and nab‐paclitaxel

A Quantitative Pharmacology Model of Exosome-Mediated Drug Efflux and Perturbation-Induced Synergy

Development and utilization of a combined LC–UV and LC–MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin

PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics

Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study

First‐in‐Human Phase I Study of Envafolimab, a Novel Subcutaneous Single‐Domain Anti‐PD‐L1 Antibody, in Patients with Advanced Solid Tumors

Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress

Ibrutinib's off-target mechanism: cause for dose optimization

Dose Optimization of Pembrolizumab: Less May Be More

IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion

Aktive Filter

Suchergebnisse filtern